Contact us Career

Press Release

AI in Drug Discovery market worth $2.97 Billion in 2026

July, 2020

" COVID-19 Impact on AI in Drug Discovery market, size, share, growth, and forecast 2020-2026 "

Artificial intelligence has the potential to transform the pharmaceutical industry. There is a significant increase in the number of applications that focus on the target and drug discovery, preclinical and clinical development, and post-approval activities.  AI can help in improving the drug approval rates, reduce development costs, swift availability of medications, and help patients comply with their treatments.

Highly complicated algorithms are becoming an essential part of drug research and discovery. The increasing number of diseases categorically epidemics and pandemics call for the fast discovery of drugs. The ever-reducing time for drug discovery, the need to reduce the drug discovery cost, and the rising adoption of cloud-based technologies have been a few driving factors of this market.

Market growth is powered by the growth of the biotechnology industry. However, the lack of data pertaining to drug discovery and the low availability of skilled labor is limiting the growth of this market. The service segment of the AI market is expected to grow more as compared to the software market.

Request for sample report @ https://www.infoholicresearch.com/request-a-sample-report/?repid=14548

AI in Drug Discovery Market research report Titled 'AI in Drug Discovery Market by Component, Technology, Application, End User, Geography- Global Opportunity Analysis and Industry Forecast up to 2026' provide in-depth analysis of key factors influencing the growth of AI in Drug Discovery size.

The report covers the AI in Drug Discovery market analysis by application, by component, by technology, by End User and by geography. It provides the analysis of the major players like InSilico Medicine, Inc., Globavir Biosciences, Inc., GNS Healthcare, Flatiron Health, Benevolent AI, Atomwise, Verge Genomics, Cloud Pharmaceuticals, and Recursion Pharmaceuticals.

This report would be the foundation for any research on the AI in Drug Discovery, vendor capabilities, SWOT of the sensors, and framework for data analysis for further advanced innovation. It is an exhaustive attempt to provide qualitative analysis for advanced research.

Access full report summary @ https://www.infoholicresearch.com/report/ai-in-drug-discovery-market/

The report consists of 100+ Tables and charts depicting the in-depth market study and the impact analysis of COVID-19 by Vendor’s name. View detailed TOC here. The scope of the study illustrated as:

  • The study covers segments of AI in Drug Discovery market by Component
    • Software
    • Services
  • The segments based on Technology covered in the study are:
    • Machine Learning
    • Deep Learning
  • Application based segmentation covered in study includes
    • Immuno-oncology
    • Neurodegenerative Diseases
    • Cardiovascular Diseases
    • Metabolic Diseases
    • Other Applications        
  • The segmentation covered based on End User is
    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations
    • Research Centers and Academic & Government Institutes
  • Geographic coverage of the study covers
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World
  • Competitive landscape covering profiles of all key players